Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS ) 19.15 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 19.15 Bid (Size) 15.32 (10) Ask (Size) 30.44 (1) Prev. Close 19.15 Today's Range 19.15 - 19.15 52wk Range 8.640 - 26.35 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November October 28, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Performance YTD +60.25% +60.25% 1 Month +7.89% +7.89% 3 Month +17.99% +17.99% 6 Month -13.74% -13.74% 1 Year +85.56% +85.56% More News Read More NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 04, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Expert Ratings For NewAmsterdam Pharma September 23, 2024 Via Benzinga NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September August 30, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside August 28, 2024 Via Benzinga NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results August 07, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results July 30, 2024 Via Benzinga Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session July 29, 2024 Via Benzinga NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations July 29, 2024 Via Investor's Business Daily NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia July 29, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 July 26, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors July 18, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors July 08, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 Via Investor's Business Daily NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office June 11, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June May 29, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings May 21, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results May 09, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 May 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
